Project Grant HT9425261E157
Award Date 6/1/26
Completion Date 5/31/28
Dollars Obligated $560K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Grant Award Summary Award Details: The Sloan-Kettering Institute for Cancer Research received a $1.39M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on September 1, 2025, with performance extending through August 31, 2029. The award supports an integrated immunomodulatory analysis of LAG3 (Lymphocyte-Activation Gene 3) inhibition in renal cell carcinoma (RCC), a hypothesis-driven research initiative addressing...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute For Cancer Research a $533,308 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2029. The award funds research titled "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma," which investigates lymphocyte-activation gene 3 (LAG3) checkpoint inhibition as a therapeutic...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $352,000 under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research for the project period September 1, 2025, through August 31, 2027. The award supports research focused on augmenting the in vivo efficacy of a novel lanosterol synthase inhibitor in glioblastoma treatment. This research aligns with the DHA's mission to transform healthcare for service...
- Federal Grant Award Summary The Sloan-Kettering Institute for Cancer Research received a $176,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025, through August 31, 2026. This award supports research investigating the interactions of mitochondrially encoded Complex I mutations with hypoxia and antitumor immune response in chromophobe renal cell carcinoma. The research aims to advance...
- Federal Grant Award Summary Award: Systematic Functional Dissection of Cancer Cell States in Lung Tumors Awardee: Sloan-Kettering Institute For Cancer Research Funding Agency: Defense Health Agency (DHA) Federal Grant Program: Military Medical Research and Development (CFDA 12.420) Award Amount: $923,805.00 Performance Period: September 1, 2025 – August 31, 2028 The Sloan-Kettering Institute for Cancer Research will conduct advanced cancer research focused on systematically analyzing...
- Federal Project Grant Award Summary The Sloan-Kettering Institute for Cancer Research received a $176,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective November 1, 2025, through October 31, 2027. The award funds research exploring a novel antibody-drug conjugate (ADC) strategy designed to block MYC protein production in neuroblastoma (NB), a pediatric cancer of the nervous system. This research...
- Federal Project Grant Award Summary The Sloan-Kettering Institute for Cancer Research received a $924,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period June 1, 2025 through May 31, 2028. The award supports research on "Therapeutic Strategies for Targeting Diverse KRAS Mutations in Lung Cancer," an initiative aligned with the DHA's mission to advance biomedical research addressing critical...
- Federal Grant Award Summary The Defense Health Agency awarded Sloan-Kettering Institute for Cancer Research $1,108,654 under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2025, for a four-year project titled "Accelerating Global Research for Relapsed or Refractory Extracranial Malignant Germ Cell Tumors" (completion date: September 29, 2029). The project delivers research and development services focused on advancing clinical care and...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $176,000 under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research to establish a mouse model of myxoid/round cell liposarcoma with endogenous translocations. The award, effective September 1, 2025, through August 31, 2027, funds basic research aimed at advancing understanding of this rare soft tissue sarcoma through the development of a preclinical...
- Federal Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $1.43M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on the identification and evaluation of immune and targeted therapies for acral melanoma. The four-year project, which commenced September 1, 2026 and concludes August 31, 2030, will be performed at the center's Tampa, Florida facility....